Biotechnology company, CytoDyn Inc. (CYDY), Thursday announced that the U.S. Food and Drug Administration or FDA had lifted clinical hold on Leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications.Following the FDA's move, the company plans to move forward with its proposed HIV clinical trial to study Leronlimab and its effects on chronic inflammation.In the pre-market activity, CytoDyn's stock is trading at $0.1603, up 0.81 percent on the Other OTC.

生物技术公司CytoDyn Inc.（CYDY）周四宣布，美国食品和药物管理局（FDA）已解除对乐诺利单抗的临床控制，乐诺利单抗是一种CCR5拮抗剂，具有多种治疗适应症的潜力。在FDA采取行动之后，该公司计划推进其拟议的HIV临床试验，以研究乐诺利单抗及其对慢性炎症的影响。在上市前活动中，CytoDyn的股价为0.1603美元，在其他场外交易中上涨0.81%。